Literature DB >> 25108710

Low-dose thrombolysis for thromboembolic lower extremity arterial occlusions is effective without major hemorrhagic complications.

H P Ebben1, J H Nederhoed1, R J Lely2, M R Meijerink2, B B van der Meijs2, W Wisselink1, K K Yeung1, A W J Hoksbergen3.   

Abstract

OBJECTIVE: To evaluate the efficacy and bleeding complications associated with a low-dose thrombolysis protocol for thromboembolic lower extremity arterial occlusions.
DESIGN: A retrospective cohort study.
MATERIALS AND METHODS: A retrospective analysis was performed using data from all consecutive patients who underwent catheter-directed, intra-arterial thrombolysis for thromboembolic lower extremity arterial occlusions between January 2004 and May 2013. All patients were treated on a standard surgical ward. Endpoints were incidence of bleeding complications, duration of thrombolysis, angiographic patency rate, 30-day mortality rate, and amputation-free rate at 6 months.
RESULTS: Of the 171 cases analyzed, 129 cases underwent low-dose thrombolysis and 42 underwent high-dose thrombolysis. No major bleeding complications occurred in the low-dose group versus 5% in the high-dose group (p = .01). The median duration of thrombolysis was 67 hours (4-304 hours) in the low-dose and 49 hours (2-171 hours) in the high-dose group (p = .027). Angiographic patency was restored in 67% of the cases in the low-dose group versus 79% of the high-dose group (p = .17). The 30-day mortality rates were 1% in the low-dose versus 5% in the high-dose group (p = .09). However, this higher mortality rate was not related to bleeding complications. Major amputation-free rates at 6 months were 81% in the low-dose group and 88% in the high-dose group (p = .22).
CONCLUSIONS: Based on this data series, low-dose thrombolysis for thromboembolic lower extremity arterial occlusions is as effective as high-dose thrombolysis; however, the risk of major bleeding complications is substantially lower when using low-dose thrombolysis.
Copyright © 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Embolism and thrombosis; Endovascular procedures; Hemorrhage; Peripheral arterial occlusive disease; Thrombolytic therapy; Urokinase-type plasminogen activator

Mesh:

Substances:

Year:  2014        PMID: 25108710     DOI: 10.1016/j.ejvs.2014.06.042

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  2 in total

1.  Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.

Authors:  William B Stubblefield; Nathan J Alves; Matthew T Rondina; Jeffrey A Kline
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

2.  Microbubbles and UltraSound-accelerated Thrombolysis (MUST) for peripheral arterial occlusions: protocol for a phase II single-arm trial.

Authors:  Harm P Ebben; Johanna H Nederhoed; Rutger J Lely; Willem Wisselink; Kakkhee Yeung
Journal:  BMJ Open       Date:  2017-08-11       Impact factor: 2.692

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.